[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2016 Japan Emerging Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

October 2015 | 590 pages | ID: 2AEE7F7381BEN
Venture Planning Group

US$ 6,080.00 US$ 7,600.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Highlights
  • Comprehensive 590-page analysis of the Japanese tumor marker testing market.
  • Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e. g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in Japanese hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.
Contains 590 pages and 95 tables
I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

1. MARKET OVERVIEW
2. WORLDWIDE MARKET STRUCTURE
3. WORLDWIDE MARKET SIZE AND GROWTH

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. BREAST CANCER
  2. LUNG CANCER
  3. COLON AND RECTUM CANCER
  4. PROSTATE CANCER
  5. STOMACH CANCER
  6. LEUKEMIA
  7. LYMPHOMA
  8. ORAL CANCER
  9. SKIN CANCER
  10. UTERINE CANCER
  11. OVARIAN CANCER
  12. BLADDER CANCER
B. Major Current And Emerging Cancer Diagnostic Tests
  1. INTRODUCTION
  2. TUMOR MARKER CLASSIFICATION
  3. ACTH
  4. ALPHA-FETOPROTEIN (AFP)
  5. BETA-2 MICROGLOBULIN
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATE-SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL TUMOR MARKERS
  27. ONCOGENES
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  28. POLYPEPTIDE GROWTH FACTORS
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
    Alpha-Interferon
    B Cell Growth Factors
    B Cell Growth Factor (BCGF)
    Gamma-Interferon
    Interleukin-1 (IL-1)
    Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING TUMOR MARKERS
    N-Acetylglucosamine
    Actin
    Alpha-Actin
    Antineuronal Antibodies
    7B2
    B72.3
    Bax
    BCD-F9
    BLCA-4
    Blood Group Antigens A,B,H
    CA
    CA 72-4/TAG-72
    CA
    CA-242
    CA-549
    CAM
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor
    Myosin
    NEA-130
    NMP22
    OA-519
    Opiod Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
  3. MOLECULAR DIAGNOSTICS
  4. CHROMOSOME ANALYSIS
a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES
E. Personal Testing

VIII. JAPAN CANCER DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

IX. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: Japan, Total Tumor Marker Test Volume and Sales Forecast by Market Segment
Japan, Estimated Cancer Death Rates Per 100,000 Population
Japan, Laboratories Performing Tumor Marker Tests by Market Segment
Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
Japan, Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test Volume
Japan, Total Tumor Marker Testing Volume Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Total Tumor Marker Sales by Major Suppliers
Japan, AFP Testing Market Diagnostics Sales by Major Supplier
Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier
Japan, PAP Testing Market Diagnostics Sales by Major Supplier
Japan, PSA Testing Market Diagnostics Sales by Major Supplier


More Publications